Jpmorgan Chase & CO Exagen Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Exagen Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 35 shares of XGN stock, worth $141. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35
Previous 35
-0.0%
Holding current value
$141
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding XGN
# of Institutions
38Shares Held
6.41MCall Options Held
4.5KPut Options Held
400-
Rtw Investments, LP New York, NY1.51MShares$6.12 Million0.07% of portfolio
-
Cowen And Company, LLC891KShares$3.61 Million0.07% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY541KShares$2.19 Million0.01% of portfolio
-
Stonepine Capital Management, LLC Bend, OR534KShares$2.16 Million1.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA491KShares$1.99 Million0.0% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $65.9M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...